Premium
Drug metabolism and androgen control therapy in prostatic cancer
Author(s) -
Sotaniemi Eero A.,
Kontturi Matti J.,
Larmi Teuvo K.
Publication year - 1973
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1973143413
Subject(s) - drug , androgen , medicine , enzyme , therapeutic index , endocrinology , metabolism , drug metabolism , cancer , androgen deprivation therapy , prostate cancer , cancer therapy , pharmacology , oncology , chemistry , biochemistry , hormone
The drug metabolizing capacity during androgen control therapy was determined in 12 patients with prostatic cancer, using plasma antipyrine half‐life as an index. In general, drug metabolizing capacity seemed impaired; the disappearance rate of the test dmg decreased in 8 of the patients. In 1 the half‐life was unchanged, and in 3 there was shortening. The results suggest that many factors simultaneously affect the drug metabolizing enzymes, and the total effect may be stimulated in the face of therapy known to inhibit these enzymes.